Skip to Content
Stock Strategist

Medtronic Takes Another Shot

It's once again leading the field in the technology for treatment-resistant hypertension.

Mentioned: , , ,

Renal denervation is on the cusp of a resurrection on the back of Medtronic’s (MDT) most recent landmark studies. A decade ago, Medtronic, St. Jude Medical, Covidien, and Boston Scientific were in hot pursuit of this technology following stellar performance in significantly lowering high blood pressure in treatment-resistant patients in several small-scale studies. But deeply disappointing results from Medtronic’s first pivotal (randomized, blinded) trial against a sham procedure put a freeze on the technology in 2014. Since then, Medtronic has refined its technology, procedure technique, and trial design to address confounds in the first pivotal study, and its second pivotal trial definitively demonstrated in 2020 that renal denervation does work independently, without the aid of antihypertensive medications. Medtronic seems to be on track for regulatory approval and commercialization in late 2022.

Renal Denervation Could Be a Significant Therapeutic Change

Debbie Wang does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.